

RNS Reach

Diaceutics PLC

Diaceutics Strengthens Leadership Team with appointment of Ken Ruppel as VP of Scientific and Medical Services

Belfast and London, 5 February - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to pharma and biotech companies, is pleased to announce the appointment of Ken Ruppel as Vice President of Scientific & Medical Services, effective February 1st 2024.

With a commitment to ensuring every patient has access to the right treatment at the right time, Diaceutics welcomes Ken to lead the expansion of current offerings and development of innovative solutions in precision medicine.

Ken joins Diaceutics with an impressive background of over 25 years' experience delivering commercial and operational success in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets. He most recently served as VP of Precision Medicine at Amplify Health, where he played a pivotal role in supporting the launch of over 20 companion diagnostic indications across diverse tumour types and laboratory methodologies in the US. His strategic expertise was instrumental in guiding Precision Medicine strategies and tactics for 12 pharmaceutical brands and his impressive track record showcases his dedication to advancing precision medicine initiatives.

In his role at Diaceutics, Ken will lead the identification, development and support of strategic growth opportunities within Scientific & Medical products and services. His responsibilities will include driving innovation and leading client interactions.

Ken's passion and expertise in diagnostic enabled therapies will play a significant role in realising the company's core mission - making precision medicine globally accessible through the DXRX platform.

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented:

"We are extremely pleased to welcome Ken to Diaceutics as our VP Scientific and Medical Services. His proven track record in Precision Medicine aligns seamlessly with our vision, and we are confident in his ability to lead our Scientific and Medical team to be a driving force towards success."

**Enquiries:
Diaceutics PLC**

Ryan Keeling, Chief Executive Officer	Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer	investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison	
Nick Harland	
Kate Hanshaw	

Alma Strategic Communications	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almastrategic.com
Kinvara Verdon	

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASSUFMLELSEFE